FGEN - FibroGen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
FGEN price evolution
FGEN
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $105.73 | $113.69 | $120.91 | $152.59 |
| Short term investments | $71.86 | $121.9 | $130.43 | $183.13 |
| Net receivables | $37.08 | $12.55 | $31.69 | $25.6 |
| Inventory | $27.34 | $41.56 | $40.7 | $41.18 |
| Total current assets | $278.17 | $331.56 | $364.11 | $411.36 |
| Long term investments | $7.43 | $6.95 | $6.61 | $8.18 |
| Property, plant & equipment | $76.92 | $81.22 | $85.76 | $91.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $87.7 | $91.97 | $96.32 | $103.77 |
| Total investments | $79.3 | $128.85 | $137.03 | $191.31 |
| Total assets | $365.87 | $423.53 | $460.43 | $515.13 |
| Current liabilities | ||||
| Accounts payable | $4.35 | $17.96 | $19.22 | $12.8 |
| Deferred revenue | $159.98 | $170.29 | $161.53 | $172.91 |
| Short long term debt | $15.23 | $14.08 | $11.88 | $11.01 |
| Total current liabilities | $196.73 | $217.67 | $209.41 | $194.07 |
| Long term debt | $186.94 | $189.88 | $190.81 | $193.62 |
| Total noncurrent liabilities | $355.29 | $368.06 | $366.21 | $381.36 |
| Total debt | $202.17 | $203.96 | $202.69 | $204.63 |
| Total liabilities | $552.02 | $585.73 | $575.63 | $575.43 |
| Shareholders' equity | ||||
| Retained earnings | -$1874.85 | -$1841.92 | -$1785.69 | -$1722.07 |
| Other shareholder equity | -$6.51 | -$6.88 | -$6.92 | -$6.25 |
| Total shareholder equity | -$228.12 | -$204.17 | -$157.17 | -$102.27 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.69 | $135.82 | $171.22 | $678.39 |
| Short term investments | $121.9 | $266.31 | $233.97 | $8.14 |
| Net receivables | $12.55 | $16.3 | $17.4 | $41.88 |
| Inventory | $41.56 | $40.44 | $31.02 | $16.53 |
| Total current assets | $331.56 | $492.83 | $474.06 | $755.11 |
| Long term investments | $6.95 | $11.48 | $173.69 | $5.04 |
| Property, plant & equipment | $81.22 | $100.93 | $120.15 | $63.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $91.97 | $117.26 | $299.76 | $71.73 |
| Total investments | $128.85 | $277.79 | $407.66 | $13.19 |
| Total assets | $423.53 | $610.09 | $773.82 | $826.84 |
| Current liabilities | ||||
| Accounts payable | $17.96 | $30.76 | $26.1 | $24.79 |
| Deferred revenue | $170.29 | $198.46 | $202.66 | $145.02 |
| Short long term debt | $14.08 | $10.29 | $10.96 | $12.33 |
| Total current liabilities | $217.67 | $273.56 | $225.5 | $163.19 |
| Long term debt | $189.88 | $17.05 | $88.78 | $25.39 |
| Total noncurrent liabilities | $368.06 | $338 | $319.21 | $222.2 |
| Total debt | $203.96 | $139.22 | $99.73 | $37.72 |
| Total liabilities | $585.73 | $631.53 | $544.71 | $385.39 |
| Shareholders' equity | ||||
| Retained earnings | -$1841.92 | -$1557.69 | -$1264.03 | -$974.01 |
| Other shareholder equity | -$6.88 | -$5.72 | -$4.16 | -$4.5 |
| Total shareholder equity | -$204.17 | -$21.45 | $209.15 | $422.18 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $55.9 | $27.14 | $40.13 | $44.32 |
| Cost of revenue | $25.75 | $5.41 | $4.24 | $5.71 |
| Gross Profit | $30.15 | $21.73 | $35.89 | $38.61 |
| Operating activities | ||||
| Research & development | $38.39 | $51.7 | $61.19 | $95.48 |
| Selling, general & administrative | $22.82 | $24.22 | $25.57 | $31.18 |
| Total operating expenses | $61.21 | $75.93 | $99.37 | $126.66 |
| Operating income | -$31.06 | -$54.2 | -$63.48 | -$88.05 |
| Income from continuing operations | ||||
| EBIT | -$27.9 | -$51.08 | -$58.51 | -$84.85 |
| Income tax expense | $0.03 | $0.08 | $0.08 | -$0.23 |
| Interest expense | $5 | $5.07 | $5.02 | $3.07 |
| Net income | ||||
| Net income | -$32.93 | -$56.23 | -$63.62 | -$87.68 |
| Income (for common shares) | -$32.93 | -$56.23 | -$63.62 | -$87.68 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $147.75 | $140.73 | $235.31 | $176.32 |
| Cost of revenue | $18.85 | $20.28 | $12.87 | $8.87 |
| Gross Profit | $128.9 | $120.45 | $222.44 | $167.45 |
| Operating activities | ||||
| Research & development | $282.86 | $296.79 | $387.04 | $252.92 |
| Selling, general & administrative | $115.25 | $124.69 | $123.92 | $106.41 |
| Total operating expenses | $410.72 | $421.48 | $510.97 | $359.33 |
| Operating income | -$281.81 | -$301.02 | -$288.53 | -$191.88 |
| Income from continuing operations | ||||
| EBIT | -$268.7 | -$291.86 | -$288.6 | -$186.53 |
| Income tax expense | $0 | $0.36 | $0.35 | $0.36 |
| Interest expense | $15.53 | $1.44 | $1.07 | $2.4 |
| Net income | ||||
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Income (for common shares) | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$32.93 | -$56.23 | -$63.62 | -$87.68 |
| Operating activities | ||||
| Depreciation | $0.82 | $1.88 | $2.38 | $2.71 |
| Business acquisitions & disposals | $0.66 | |||
| Stock-based compensation | $8.76 | $9.3 | $9.48 | $15.88 |
| Total cash flows from operations | -$59.29 | -$18.32 | -$84.54 | -$110.57 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.25 | -$0.68 | -$0.99 |
| Investments | $51.3 | $10.49 | $54.9 | -$13.95 |
| Total cash flows from investing | $51.28 | $10.24 | $54.22 | -$14.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | $20.44 | ||
| Net borrowings | -$0.01 | -$0.05 | -$0.02 | $71.1 |
| Total cash flows from financing | -$0.17 | -$0.25 | -$0.02 | $91.53 |
| Effect of exchange rate | $0.22 | $1.1 | -$1.33 | -$2.64 |
| Change in cash and equivalents | -$7.95 | -$7.23 | -$31.67 | -$35.97 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Operating activities | ||||
| Depreciation | $9.93 | $10.6 | $14.81 | $22.05 |
| Business acquisitions & disposals | $0.66 | -$35 | -$25 | -$2.83 |
| Stock-based compensation | $50.77 | $65.6 | $71.16 | $72.72 |
| Total cash flows from operations | -$315.02 | -$145.93 | -$82.23 | $81.6 |
| Investing activities | ||||
| Capital expenditures | -$2.52 | -$3.73 | -$5.19 | -$3.99 |
| Investments | $155.52 | $127.85 | -$396.79 | $459.31 |
| Total cash flows from investing | $153.66 | $89.12 | -$426.97 | $452.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $52.14 | $4.18 | $12.7 | $37.83 |
| Net borrowings | $70.85 | $47.76 | -$5.89 | -$13.02 |
| Total cash flows from financing | $122.75 | $46.78 | -$0.56 | $13.34 |
| Effect of exchange rate | -$3.4 | -$5.48 | $2.6 | $4.7 |
| Change in cash and equivalents | -$42.01 | -$15.52 | -$507.17 | $552.13 |
News
|
FibroGen Shares Climb On Strong Q1 Sales - FibroGen (NASDAQ:FGEN)
Benzinga
7 May 2024
|
|
Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com
7 May 2024
|
|
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
7 May 2024
|
|
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day...
Benzinga
7 May 2024
|
|
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Zacks via Yahoo Finance
21 Mar 2024
|
|
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Zacks via Yahoo Finance
20 Mar 2024
|
|
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
InvestorPlace
20 Mar 2024
|
|
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Zacks via Yahoo Finance
15 Mar 2024
|
|
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
Zacks via Yahoo Finance
14 Mar 2024
|
|
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
Zacks via Yahoo Finance
13 Mar 2024
|
Fundamentals
| Market cap | $115.39M |
|---|---|
| Enterprise value | $211.83M |
| Shares outstanding | 99.47M |
| Revenue | $167.49M |
|---|---|
| EBITDA | -$214.56M |
| EBIT | -$222.34M |
| Net Income | -$240.46M |
| Revenue Q/Q | 54.59% |
| Revenue Y/Y | 44.30% |
| P/E ratio | -0.48 |
|---|---|
| EV/Sales | 1.26 |
| EV/EBITDA | -0.99 |
| EV/EBIT | -0.95 |
| P/S ratio | 0.69 |
| P/B ratio | -0.52 |
| Book/Share | -2.23 |
| Cash/Share | 1.06 |
| EPS | -$2.42 |
|---|---|
| ROA | -54.50% |
| ROE | 139.05% |
| Debt/Equity | -2.87 |
|---|---|
| Net debt/EBITDA | -2.08 |
| Current ratio | 1.41 |
| Quick ratio | 1.27 |